Related Experiment Video
Updated: Feb 5, 2026
Primary Human Nasal Epithelial Cells: Biobanking in the Context of Precision Medicine
Published on: April 22, 2022
Precision Medicine for Primary Central Nervous System Tumors: Are We There Yet?
Franziska Maria Ippen1, Howard Colman1, Martin J van den Bent1
1From the Massachusetts General Hospital, Harvard Medical School, Boston, MA; Departments of Neurosurgery, Neurology, and Internal Medicine (Oncology), Huntsman Cancer Institute, University of Utah, Salt Lake City, UT; Department of Neurology, The Brain Tumor Center at Erasmus MC Cancer Institute, Rotterdam, Netherlands; Division of Neuro-Oncology, Stephen E. and Catherine Pappas Center for Neuro-Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA.
Abstract:
In recent years, technologic advances have increased tremendously our understanding of the molecular characteristics and genetic drivers of a variety of brain tumors. These discoveries have led to paradigm shifts in the treatment of these tumor entities and may therefore have a considerable impact on the outcome of affected patients in the near future. Here, we provide a broad overview of recently discovered clinically actionable mutations that have been identified in three different primary brain tumors: gliomas, meningiomas, and craniopharyngiomas. We furthermore highlight the diagnostic and therapeutic implications of these findings and summarize recently published and ongoing trials.
Insights
Technological advances have improved understanding of brain tumor molecular features and genetic drivers. This knowledge is shifting treatment paradigms for gliomas, meningiomas, and craniopharyngiomas, potentially improving patient outcomes.
Area of Science:
- Neuro-oncology
- Molecular Biology
- Genetics
Background:
- Recent technological advancements have significantly enhanced the understanding of brain tumor molecular characteristics.
- Genetic drivers are increasingly recognized as crucial in the development and progression of primary brain tumors.
- This evolving knowledge is prompting a re-evaluation of current treatment strategies.
Purpose of the Study:
- To provide a comprehensive overview of clinically actionable mutations identified in gliomas, meningiomas, and craniopharyngiomas.
- To highlight the diagnostic and therapeutic implications of these genetic discoveries.
- To summarize recent and ongoing clinical trials related to these brain tumor mutations.
Main Methods:
- Literature review of recent scientific publications.
- Analysis of identified clinically actionable mutations in primary brain tumors.
- Synthesis of diagnostic and therapeutic implications.
Main Results:
- Identification of key molecular alterations and actionable mutations in gliomas, meningiomas, and craniopharyngiomas.
- Demonstration of the impact of these mutations on diagnostic approaches.
- Overview of emerging targeted therapies and ongoing clinical trials.
Conclusions:
- Advances in molecular understanding are revolutionizing brain tumor treatment.
- Targeted therapies based on specific mutations offer new hope for improved patient outcomes.
- Continued research and clinical trials are essential to translate these discoveries into clinical practice.
Related Concept Videos
01:25What is a Nervous System?
01:14The Parasympathetic Nervous System
01:25The Sympathetic Nervous System
01:25The Central Dogma
01:21Nervous System
02:16Measures of Central Tendency